Syros Pharmaceuticals Inc (SYRS)

NASDAQ
4.530
-0.100(-2.16%)
After Hours
4.550
+0.020(+0.441%)
- Real-time Data
  • Volume:
    307,297
  • Bid/Ask:
    4.500/4.550
  • Day's Range:
    4.510 - 4.750

SYRS Overview

Prev. Close
4.63
Day's Range
4.51-4.75
Revenue
19.52M
Open
4.71
52 wk Range
4-15.59
EPS
-1.63
Volume
307,297
Market Cap
280.55M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
548,801
P/E Ratio
-
Beta
1.92
1-Year Change
-46.07%
Shares Outstanding
61,930,800
Next Earnings Date
Nov 16, 2021
What is your sentiment on Syros Pharmaceuticals Inc?
or
Market is currently closed. Voting is open during market hours.

Syros Pharmaceuticals Inc News

Syros Pharmaceuticals Inc Analysis

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong SellStrong SellStrong SellStrong SellStrong Sell
Technical IndicatorsStrong SellStrong SellStrong SellSellStrong Sell
SummaryStrong SellStrong SellStrong SellStrong SellStrong Sell

Syros Pharmaceuticals Inc Company Profile

Syros Pharmaceuticals Inc Company Profile

Sector
Services
Employees
103

Syros Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on redefining the power of small molecules to control the expression of genes. It is focused on developing treatments for cancer and diseases resulting from mutations of a single gene (monogenic diseases) and building a pipeline of gene control medicines. Its product candidates include SY-1425, SY-5609 and SY-2101. SY-1425 is a selective retinoic acid receptor alpha (RAR), agonist that is being evaluated in combination with azacytidine, used to treat acute myeloid leukemia (AML). SY-5609 is a selective and potent oral inhibitor of cyclin-dependent kinase 7 (CDK7) that is being evaluated in the dose escalation portion in patients with select advanced solid tumors. SY-2101 is an oral form of arsenic trioxide (ATO) being developed for the treatment of AML.

Read More
  • wow this call option works horrible.. dont even try....drop 25
    0
    • 5.85 long now good price techinally..
      0
      • media always wrong.....stay away
        0
        • softbank starting to investing boitech
          0
          • wallstreetbeats - reddit targeting Gene editing biotech owned by ARK, this will be one of them
            0
            • ARK buying shares increasing to own 25%
              0
              • Miss ark can you buy some more syrs plz :p
                0
                • So i bought the stock right after the massive drop of 30%. For 2 months i was consistently losing money on it. However it has now spiked like it should. I expect a 10 dollar range by the end of next week.
                  0
                  • Strong like bull
                    0
                    • extremely!  especially today.
                      0
                    • I bought in on the panic from other investors. I have strong confidence in this company, especially with the upcoming income numbers coming out in November.
                      0
                  Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
                  Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.